Former Mahindra CEO Pawan Goenka joins Bosch and Sun Pharmaceutical as an independent director

Former Mahindra CEO Pawan Goenka joins Bosch and Sun Pharmaceutical as an independent director

FPJ Web DeskUpdated: Friday, May 21, 2021, 12:00 AM IST
article-image
Former Mahindra MD Pawan Goenka joins Bosch and Sun Pharmaceutical as an independent director | twitter

Pawan Goenka, former managing director of Mahindra & Mahindra, retired on April 1 from the company. Now, he has joined the board of technology and engineering company Bosch as an independent director and board of drug firm Sun Pharmaceutical as an additional independent director.

In both companies, he has been appointed to the board from May 21, 2021. The board of directors at Bosch approved the appointment of Pawan Kumar Goenka as independent director for a period of five years with effect from May 21, 2021.

Goenka served on the boards of several Mahindra Group Companies both domestic and International.

Goenka was appointed Executive Director and President (AFS) on the Board of Mahindra & Mahindra in September 2013. He retired from Mahindra as Managing Director and CEO on April 1, 2021.

He joined Mahindra & Mahindra Ltd as General Manager (R&D). During his R&D tenure he led the development of the Scorpio SUV. He was appointed COO (Automotive Sector) in April 2003, President (Automotive Sector) in September 2005, President (Automotive & Farm Equipment Sectors) in April 2010.

Prior to joining M&M, he worked at General Motors R&D Centre in the USA from 1979 to 1993.

RECENT STORIES

Avantel Q3 FY26 Net Profit Rises 28% YoY To ₹32.9 Cr, Revenue Grows 25% To ₹441 Crore
Avantel Q3 FY26 Net Profit Rises 28% YoY To ₹32.9 Cr, Revenue Grows 25% To ₹441 Crore
Pakistan Faces Deep Investment Crisis, High Costs & Policy Uncertainty Drive Investors Away
Pakistan Faces Deep Investment Crisis, High Costs & Policy Uncertainty Drive Investors Away
RBI Could Cut Interest Rates Further If India–US Trade Deal Is Delayed, Says Goldman Sachs
RBI Could Cut Interest Rates Further If India–US Trade Deal Is Delayed, Says Goldman Sachs
Rupee Falls To 92 Against Dollar, Imports & Foreign Spending Get Costlier While Exporters See Relief
Rupee Falls To 92 Against Dollar, Imports & Foreign Spending Get Costlier While Exporters See Relief
DCCDL Q3 Rental Income Jumps 18% To Rs 1,412 Crore, Strong Demand Boosts Office & Retail Assets
DCCDL Q3 Rental Income Jumps 18% To Rs 1,412 Crore, Strong Demand Boosts Office & Retail Assets